Previous studies had demonstrated synergy between PARP and PI3K inhibitors in BRCA1-deficient mouse models [74] and shown that PI3K blockade promotes homologous recombination deficiency by downregulating BRCA, thereby sensitising BRCA-proficient tumours to PARP inhibition [75]. The gene discussed is PIK3CD; the disease is neoplasm.